Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions.
|
30050407 |
2018 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Importantly, APP/PS1/δ<sup>D910A</sup> mice exhibited no spatial learning or memory deficits.
|
31363064 |
2019 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Increased ILK expression of dentate gyrus (DG) rescued the hippocampus-dependent neurogenesis and memory deficits in APP/PS1 mice.
|
29787769 |
2018 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Increase in presenilin 1 (PS1) levels in senescence-accelerated mice (SAMP8) may indirectly impair memory by affecting amyloid precursor protein (APP) processing.
|
19181896 |
2009 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Here, we confirmed that four weeks' treatment of exendin-4 could rescue memory deficits and neuropathological changes in APP/PS1 mice.
|
29223528 |
2018 |
Memory impairment
|
0.500 |
GeneticVariation
|
phenotype |
BEFREE |
BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.
|
17258906 |
2007 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
First, silibinin and silymarin administration could alleviate memory deficits and reduce the amyloid plaque burden in the brain of APP/PS1 mice in comparison with controls.
|
31236617 |
2019 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Restraint/isolation stress induced significant depressive-like behaviors in APP/PS1 mice at 4 months of age and memory impairment at 10 months of age, while 6 months of icariin administration relieved the memory damage.
|
31001073 |
2019 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
HPO |
|
|
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we evaluated the therapeutic effect of WJ-MSC transplantation on the neuropathology and memory deficits in amyloid precursor protein (APP) and presenilin-1 (PS1) double-transgenic mice and discussed the mechanism.
|
26188488 |
2016 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
|
28065587 |
2017 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
The studied dendrimers did not reverse memory impairment in APP/PS1 mice following chronic administration; moreover, cationic G4mOS caused cognitive decline in nontransgenic mice.
|
24004423 |
2013 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Thus far, the one manipulation found to mitigate the learning and memory deficits in APP transgenic mice is immunotherapy for A beta, either using active or passive immunization against the peptide.
|
12737527 |
2003 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
SNX8 Enhances Non-amyloidogenic APP Trafficking and Attenuates Aβ Accumulation and Memory Deficits in an AD Mouse.
|
31551717 |
2019 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
We show that inhibition of APP cleavage by β-secretase rescues synaptic/memory deficits in a mouse model of FDD.
|
22170863 |
2012 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Second, we used an APPswe/PS1E9 (APP/PS1) double transgenic mice to evaluate the amelioration ability of simvastatin against the memory impairment in vivo.
|
28528185 |
2017 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Behavioral tests further confirmed PTS' potential of overcoming memory deficits in APP/PS1 mice (AD model).
|
31737188 |
2019 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Although Abeta derived from the Abeta precursor protein (beta-APP) is believed to play a central etiological role in AD, it is not clear whether soluble and/or fibrillar forms are responsible for the memory deficit.
|
11724968 |
2001 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
An efficacy test carried out in APP/PS1 transgenic mice showed a reduction of memory deficit in mice chronically treated with PGZ-NPs.
|
30271148 |
2018 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Here, we showed that systemic treatment of APP and presenilin 1 (PS1) transgenic mice, a robust Alzheimer's disease (AD) mouse model, with indirubin-3'-monoxime (IMX; 20mg/kg; 3 times weekly), for as little as 2months, significantly attenuated spatial memory deficits.
|
20381617 |
2010 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that xanthoceraside at doses of 0.08 and 0.32 mg/kg/d for 6 months significantly improved learning and memory impairment in APP transgenic mice assessed by the Y maze and novel object recognition tests.
|
24810883 |
2014 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
In contrast, C57 APP/PS1 and SAMP8 wild type mice were inconspicuous in all of these tasks and properties except C57 APP/PS1 mice which showed motor memory impairment in the shuttle box task at 9 months old.
|
24095271 |
2013 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Xanthoceraside administration alleviated learning-memory deficits and increased the LTP in APP/PS1 transgenic mice.
|
29124300 |
2018 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Here we aimed to determine whether chronic treatment with the α(2)-adrenoceptor antagonist fluparoxan, that enhances noradrenaline release, can prevent the onset of Alzheimer's-like pathology and memory deficits in APP/PS1 transgenic mice (TASTPM).
|
20850464 |
2011 |
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
In addition, age-dependent spatial memory deficits in APP/PS1 mice were reversed in TRPM2(-/-)/APP/PS1 mice.
|
26558786 |
2015 |